Versacloz is owned by Tasman Pharma.
Versacloz contains Clozapine.
Versacloz has a total of 1 drug patent out of which 0 drug patents have expired.
Versacloz was authorised for market use on 06 February, 2013.
Versacloz is available in suspension;oral dosage forms.
The generics of Versacloz are possible to be released after 01 May, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8057811||TASMAN PHARMA||Stable clozapine suspension formulation|| |
(5 years from now)
Market Authorisation Date: 06 February, 2013
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic